Sangamo Therapeutics (SGMO) Tops Q1 EPS by 1c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $27.29 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance